Nektar Therapeutics Payments to Acquire Available-for-sale Securities
Nektar Therapeutics (NKTR) reported Payments to Acquire Available-for-sale Securities of $1.94 billion for the 9-month period ending 2018-09-30, per its 10-Q filed 2018-11-08.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecurities · last filed 2018-11-08
- Nektar Therapeutics payments to acquire available-for-sale securities for the quarter ending 2018-09-30 was $954.33M, a 393.69% increase year-over-year.
- Nektar Therapeutics payments to acquire available-for-sale securities for the quarter ending 2018-06-30 was $989.85M, a 2086.16% increase year-over-year.
- Nektar Therapeutics payments to acquire available-for-sale securities for the quarter ending 2018-03-31 was $0.00, a 100.00% decline year-over-year.
- Nektar Therapeutics payments to acquire available-for-sale securities for the quarter ending 2017-12-31 was $89.99M, a 53.06% decline year-over-year.
- Nektar Therapeutics payments to acquire available-for-sale securities for fiscal 2017 was $404.43M, a 20.85% increase from fiscal 2016.
- Nektar Therapeutics payments to acquire available-for-sale securities for fiscal 2016 was $334.66M, a 12.45% increase from fiscal 2015.
- Nektar Therapeutics payments to acquire available-for-sale securities for fiscal 2015 was $297.61M, a 0.12% increase from fiscal 2014.
- Nektar Therapeutics payments to acquire available-for-sale securities for fiscal 2014 was $297.25M, a 10.89% increase from fiscal 2013.
| Period end | Payments to Acquire Available-for-sale Securities 3 month | Payments to Acquire Available-for-sale Securities 6 month | Payments to Acquire Available-for-sale Securities 9 month | Payments to Acquire Available-for-sale Securities 12 month |
|---|---|---|---|---|
| 2018-09-30 | $954.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $1.94B derived: sum of 2 quarters · filed 2018-11-08 | $1.94B 10-Q · filed 2018-11-08 | $2.03B derived: sum of 4 quarters · filed 2018-11-08 |
| 2018-06-30 | $989.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $989.85M 10-Q · filed 2018-08-09 | $1.08B derived: sum of 3 quarters · filed 2018-08-09 | $1.27B derived: sum of 4 quarters · filed 2018-11-08 |
| 2018-03-31 | $0.00 10-Q · filed 2018-05-10 | $89.99M derived: sum of 2 quarters · filed 2018-05-10 | $283.29M derived: sum of 3 quarters · filed 2018-11-08 | $328.57M derived: sum of 4 quarters · filed 2018-11-08 |
| 2017-12-31 | $89.99M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $283.29M derived: sum of 2 quarters · filed 2018-11-08 | $328.57M derived: sum of 3 quarters · filed 2018-11-08 | $404.43M 10-K · filed 2018-03-01 |
| 2017-09-30 | $193.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $238.58M derived: sum of 2 quarters · filed 2018-11-08 | $314.44M 10-Q · filed 2018-11-08 | $506.13M derived: sum of 4 quarters · filed 2018-11-08 |
| 2017-06-30 | $45.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $121.14M 10-Q · filed 2018-08-09 | $312.82M derived: sum of 3 quarters · filed 2018-08-09 | $382.99M derived: sum of 4 quarters · filed 2018-08-09 |
| 2017-03-31 | $75.86M 10-Q · filed 2018-05-10 | $267.54M derived: sum of 2 quarters · filed 2018-05-10 | $337.71M derived: sum of 3 quarters · filed 2018-05-10 | $379.06M derived: sum of 4 quarters · filed 2018-05-10 |
| 2016-12-31 | $191.69M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $261.85M derived: sum of 2 quarters · filed 2018-03-01 | $303.21M derived: sum of 3 quarters · filed 2018-03-01 | $334.66M 10-K · filed 2018-03-01 |
| 2016-09-30 | $70.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $111.52M derived: sum of 2 quarters · filed 2017-11-08 | $142.97M 10-Q · filed 2017-11-08 | $237.71M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-06-30 | $41.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $72.81M 10-Q · filed 2017-08-09 | $167.54M derived: sum of 3 quarters · filed 2018-03-01 | $245.95M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-03-31 | $31.45M 10-Q · filed 2017-05-10 | $126.19M derived: sum of 2 quarters · filed 2018-03-01 | $204.59M derived: sum of 3 quarters · filed 2018-03-01 | $304.63M derived: sum of 4 quarters · filed 2018-03-01 |
| 2015-12-31 | $94.74M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $173.14M derived: sum of 2 quarters · filed 2018-03-01 | $273.18M derived: sum of 3 quarters · filed 2018-03-01 | $297.61M 10-K · filed 2018-03-01 |
| 2015-09-30 | $78.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | $178.44M derived: sum of 2 quarters · filed 2016-11-04 | $202.87M 10-Q · filed 2016-11-04 | $299.96M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | $100.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $124.47M 10-Q · filed 2016-08-04 | $221.56M derived: sum of 3 quarters · filed 2017-03-01 | $255.22M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-03-31 | $24.43M 10-Q · filed 2016-05-04 | $121.52M derived: sum of 2 quarters · filed 2017-03-01 | $155.19M derived: sum of 3 quarters · filed 2017-03-01 | $211.02M derived: sum of 4 quarters · filed 2017-03-01 |
| 2014-12-31 | $97.09M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $130.75M derived: sum of 2 quarters · filed 2017-03-01 | $186.59M derived: sum of 3 quarters · filed 2017-03-01 | $297.25M 10-K · filed 2017-03-01 |
| 2014-09-30 | $33.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | $89.50M derived: sum of 2 quarters · filed 2015-11-06 | $200.16M 10-Q · filed 2015-11-06 | $327.66M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-06-30 | $55.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | $166.50M 10-Q · filed 2015-08-06 | $294.00M derived: sum of 3 quarters · filed 2016-02-29 | $325.16M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-03-31 | $110.66M 10-Q · filed 2015-05-01 | $238.16M derived: sum of 2 quarters · filed 2016-02-29 | $269.33M derived: sum of 3 quarters · filed 2016-02-29 | $322.39M derived: sum of 4 quarters · filed 2016-02-29 |
| 2013-12-31 | $127.50M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $158.67M derived: sum of 2 quarters · filed 2016-02-29 | $211.73M derived: sum of 3 quarters · filed 2016-02-29 | $268.07M 10-K · filed 2016-02-29 |
| 2013-09-30 | $31.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | $84.23M derived: sum of 2 quarters · filed 2014-11-07 | $140.57M 10-Q · filed 2014-11-07 | $178.62M derived: sum of 4 quarters · filed 2015-02-26 |
| 2013-06-30 | $53.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-01 | $109.40M 10-Q · filed 2014-08-01 | $147.45M derived: sum of 3 quarters · filed 2015-02-26 | $153.65M derived: sum of 4 quarters · filed 2015-02-26 |
| 2013-03-31 | $56.34M 10-Q · filed 2014-05-08 | $94.39M derived: sum of 2 quarters · filed 2015-02-26 | $100.59M derived: sum of 3 quarters · filed 2015-02-26 | $118.97M derived: sum of 4 quarters · filed 2015-02-26 |
| 2012-12-31 | $38.05M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-26 | $44.25M derived: sum of 2 quarters · filed 2015-02-26 | $62.64M derived: sum of 3 quarters · filed 2015-02-26 | $164.66M 10-K · filed 2015-02-26 |
| 2012-09-30 | $6.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | $24.59M derived: sum of 2 quarters · filed 2013-11-07 | $126.61M 10-Q · filed 2013-11-07 | $194.45M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-06-30 | $18.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | $120.41M 10-Q · filed 2013-08-09 | $188.25M derived: sum of 3 quarters · filed 2014-02-27 | $306.10M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-03-31 | $102.02M 10-Q · filed 2013-05-09 | $169.87M derived: sum of 2 quarters · filed 2014-02-27 | $287.71M derived: sum of 3 quarters · filed 2014-02-27 | $424.67M derived: sum of 4 quarters · filed 2014-02-27 |
| 2011-12-31 | $67.84M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-27 | $185.69M derived: sum of 2 quarters · filed 2014-02-27 | $322.65M derived: sum of 3 quarters · filed 2014-02-27 | $695.37M 10-K · filed 2014-02-27 |
| 2011-09-30 | $117.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09 | $254.81M derived: sum of 2 quarters · filed 2012-11-09 | $627.53M 10-Q · filed 2012-11-09 | $755.49M derived: sum of 4 quarters · filed 2013-03-01 |
| 2011-06-30 | $136.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-09 | $509.68M 10-Q · filed 2012-08-09 | $637.64M derived: sum of 3 quarters · filed 2013-03-01 | $734.53M derived: sum of 4 quarters · filed 2013-03-01 |
| 2011-03-31 | $372.72M 10-Q · filed 2012-05-04 | $500.69M derived: sum of 2 quarters · filed 2013-03-01 | $597.57M derived: sum of 3 quarters · filed 2013-03-01 | $700.57M derived: sum of 4 quarters · filed 2013-03-01 |
| 2010-12-31 | $127.96M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-01 | $224.85M derived: sum of 2 quarters · filed 2013-03-01 | $327.85M derived: sum of 3 quarters · filed 2013-03-01 | $443.12M 10-K · filed 2013-03-01 |
| 2010-09-30 | $96.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-04 | $199.88M derived: sum of 2 quarters · filed 2011-11-04 | $315.16M 10-Q · filed 2011-11-04 | |
| 2010-06-30 | $103.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-05 | $218.28M 10-Q · filed 2011-08-05 | ||
| 2010-03-31 | $115.28M 10-Q · filed 2011-04-29 | |||
| 2009-12-31 | $451.92M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |